COMPLETED Clinical Trials

A phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas

TYPE OF SARCOMA: Undifferentiated Pleomorphic Sarcoma and Poorly Differentiated/Dedifferentiated Liposarcoma
DRUG: Pembrolizumab
ACCRUAL STATUS: Completed

A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors

TYPE OF SARCOMA: Gastrointestinal stromal tumors
DRUG: OSI-906
ACCRUAL STATUS: Completed

A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

TYPE OF SARCOMA: Locally advanced or metastatic soft tissue sarcoma
DRUG: TH-302 combined with doxorubicin vs. doxorubicin alone
ACCRUAL STATUS: Completed

Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma

TYPE OF SARCOMA: Advanced or Metastatic Untreated Soft Tissue Sarcoma
DRUG: Trabectedin Infused to Doxorubicin
ACCRUAL STATUS: Terminated

Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

TYPE OF SARCOMA: Metastatic GIST
DRUG: Imatinib
ACCRUAL STATUS: Terminated

SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma

TYPE OF SARCOMA: Metastatic Leiomyosarcoma
DRUG: Mocetinostat & Gemcitabine
ACCRUAL STATUS: Completed

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

TYPE OF SARCOMA: Ewing’s sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma
DRUG: R1507
ACCRUAL STATUS: Completed

Trial of Dasatinib in Advanced Sarcomas

TYPE OF SARCOMA: Leiomyosarcoma, liposarcoma, MFH/pleomorphic undifferentiated sarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, osteosarcoma (skeletal or extraosseous), chondrosarcoma, ewing’s, alveolar soft part sarcoma, chordoma, epithelioid sarcoma, giant cell tumor of bone, hemangiopericytoma/solitary fibrous tumor, gastrointestinal stromal tumors (GIST)
DRUG: Dasatinib
ACCRUAL STATUS: Completed

A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas

TYPE OF SARCOMA: Chondrosarcoma, extra-skeletal myxoid chondrosarcoma or alveolar soft part sarcoma
DRUG: Perifosine
ACCRUAL STATUS: Completed

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

TYPE OF SARCOMA: Malignant peripheral nerve sheath tumors sporadic or NF1 associated
DRUG: Adriamycin/ifosfamide and Adriamycin/etoposide
ACCRUAL STATUS: Completed

Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

TYPE OF SARCOMA: Uterine Leiomyosarcoma
DRUG: Gemcitabine and Docetaxel
ACCRUAL STATUS: Completed

Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

TYPE OF SARCOMA: Dermatofirbrosarcoma Protuberans
DRUG: Gleevec (Imatinib Mesylate)
ACCRUAL STATUS: Completed

Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing’s Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

TYPE OF SARCOMA: Recurrent Ewing’s Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma
DRUG: Gemcitabine and Docetaxel
ACCRUAL STATUS: Completed

Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma

TYPE OF SARCOMA: Unresectable soft tissue sarcoma
DRUG: Gemcitabine and Docetaxel
ACCRUAL STATUS: Completed

Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma

TYPE OF SARCOMA: Ewing’s Family (including PNET), OsteosarcomaSynovial Sarcoma, Leiomyosarcoma, Rhabdomyosarcoma (including alveolar, embryonal and pleomorphic), Liposarcoma (all variants), Malignant Fibrous Histiocytoma, Peripheral Nerve Sheath (including MPNST, neurofibrosarcoma, schwannoma), Fibrosarcoma, Angiosarcoma (all variants), Desmoid Tumor, GI Stromal (c-kit negative only)
DRUG: Imatinib Mesylate (Gleevec)
ACCRUAL STATUS: Completed

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma

TYPE OF SARCOMA: Ewing Sarcoma
DRUG: Niraparib, Temozolomide and Irinotecan
ACCRUAL STATUS: Not Recruiting